Bill

Bill > S2074


US S2074

US S2074
Mainstreaming Addiction Treatment Act of 2019


summary

Introduced
07/10/2019
In Committee
07/10/2019
Crossed Over
Passed
Dead
12/31/2020

Introduced Session

116th Congress

Bill Summary

A BILL To amend section 303(g) of the Controlled Substances Act (21 U.S.C. 823(g)) to eliminate the separate registration requirement for dispensing narcotic drugs in schedule III, IV, or V, such as buprenorphine, for maintenance or detoxification treatment, and for other purposes. 1

AI Summary

This bill aims to eliminate the separate registration requirement for practitioners to dispense certain narcotic drugs, such as buprenorphine, for maintenance or detoxification treatment. It amends the Controlled Substances Act to remove the need for practitioners to obtain a separate registration to prescribe these drugs, which are classified as Schedule III, IV, or V substances. Additionally, the bill directs the Secretary of Health and Human Services to conduct a national education campaign to encourage practitioners to integrate substance use treatment into their practices and provide information on available educational resources. The bill also allows community health aides and practitioners to dispense these narcotic drugs without being registered, as long as the drugs are prescribed through telemedicine.

Committee Categories

Health and Social Services

Sponsors (6)

Last Action

Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (on 07/10/2019)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...